MK 1167
Alternative Names: MK-1167Latest Information Update: 30 Dec 2024
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Class Antidementias; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 24 Dec 2024 Phase-II clinical trials in Alzheimer's disease (Adjunctive treatment) in USA (PO) (NCT06721156)
- 06 Dec 2024 Merck Sharp & Dohme plans a phase II trial for Alzheimer's disease (Adjunctive therapy) in December 2024 (PO, Capsule) (NCT06721156)
- 23 Sep 2024 Merck Sharp & Dohme completes a phase I trial for Alzheimer's disease (Adjunctive treatment) (PO, Capsule) in the US (NCT06285240)